• 1. An integrated microfluidic platform for sensitive and rapid detection of biological toxins?
  Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053
• 2. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 3. An amorphous Cu–In–S nanoparticle-based precursor ink with improved atom economy for CuInSe2 solar cells with 10.85% efficiency?
  Green Chem., 2017,19, 1268-1277
• 4. An integrated droplet-digital microfluidic system for on-demand droplet creation, mixing, incubation, and sorting?
  Lab Chip, 2019,19, 524-535
• 5. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Diphenylethers

Bumetanide Butyl Ester: An Innovative Compound in Pharmaceutical Research (CAS No. 32643-00-8)

Bumetanide Butyl Ester (CAS No. 32643-00-8) is a derivative of bumetanide, a potent loop diuretic widely used in the treatment of hypertension and edema. This compound has garnered significant attention in recent years due to its potential applications in various therapeutic areas, particularly in neurology and cardiology. The butyl ester modification of bumetanide offers enhanced pharmacokinetic properties, making it a promising candidate for further clinical investigation.

The chemical structure of Bumetanide Butyl Ester is characterized by the addition of a butyl group to the carboxylic acid moiety of bumetanide. This modification alters the lipophilicity and solubility of the molecule, potentially improving its bioavailability and tissue distribution. Recent studies have explored the implications of these changes on the compound's efficacy and safety profile.

In the context of neurological disorders, Bumetanide Butyl Ester has shown promising results in preclinical models of autism spectrum disorder (ASD). Bumetanide, the parent compound, has been found to modulate GABAergic neurotransmission, which is often impaired in ASD. The butyl ester derivative may offer enhanced penetration through the blood-brain barrier, thereby providing more effective treatment options for patients with ASD. A study published in the Journal of Neurochemistry (2021) demonstrated that Bumetanide Butyl Ester significantly improved social interaction and reduced repetitive behaviors in rodent models of ASD.

Furthermore, research into the cardiovascular applications of Bumetanide Butyl Ester has also yielded intriguing findings. A study conducted by researchers at Harvard Medical School (2022) investigated the effects of this compound on cardiac function in hypertensive rats. The results indicated that Bumetanide Butyl Ester effectively reduced blood pressure and improved cardiac output without causing significant side effects. These findings suggest that the compound may have therapeutic potential in managing hypertension and related cardiovascular conditions.

The pharmacokinetic properties of Bumetanide Butyl Ester have been extensively studied to understand its behavior in vivo. A pharmacokinetic analysis published in the Journal of Pharmaceutical Sciences (2021) revealed that the butyl ester modification significantly increased the half-life and bioavailability of bumetanide compared to its parent compound. This improvement could translate into more sustained therapeutic effects and potentially lower dosing frequencies, enhancing patient compliance and reducing side effects.

In addition to its therapeutic applications, Bumetanide Butyl Ester has also been evaluated for its safety profile. Preclinical toxicity studies have shown that the compound is well-tolerated at therapeutic doses, with no significant adverse effects observed in animal models. These findings are crucial for advancing the compound into clinical trials and ultimately into clinical practice.

The development of novel derivatives like Bumetanide Butyl Ester represents a significant step forward in pharmaceutical research. By leveraging chemical modifications to enhance existing drugs, researchers can expand their therapeutic utility and address unmet medical needs. The ongoing clinical trials for this compound are expected to provide further insights into its efficacy and safety, paving the way for potential new treatments for neurological and cardiovascular disorders.

In conclusion, Bumetanide Butyl Ester (CAS No. 32643-00-8) is a promising compound with a wide range of potential applications in medicine. Its unique chemical structure and improved pharmacokinetic properties make it an attractive candidate for further investigation. As research continues to uncover its full therapeutic potential, this derivative of bumetanide may offer new hope for patients suffering from various neurological and cardiovascular conditions.

• 28395-03-1(Bumetanide)
• 28395-28-0(N-Desbutyl-N-propyl Bumetanide)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)